Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M4PH
|
||||
| Former ID |
DIB009174
|
||||
| Drug Name |
LOXO-101
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Company |
Array biopharma; loxo oncology
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | BDNF/NT-3 growth factors receptor | Target Info | Inhibitor | [2] | |
| Trk receptor | Target Info | Inhibitor | [3] | ||
| Neurotrophic tyrosine kinase receptor 1 | Target Info | Inhibitor | [4] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Neurotrophin signaling pathway | |||||
| Alcoholismhsa04010:MAPK signaling pathway | |||||
| Endocytosis | |||||
| Apoptosis | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Thyroid cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | SHP2 signaling | ||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Neurotrophic factor-mediated Trk receptor signalingtrkrpathway:Neurotrophic factor-mediated Trk receptor signaling | |||||
| Reactome | NGF-independant TRKA activationR-HSA-170984:ARMS-mediated activation | ||||
| NGF-independant TRKA activation | |||||
| PI3K/AKT activationR-HSA-170968:Frs2-mediated activation | |||||
| ARMS-mediated activation | |||||
| PI3K/AKT activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| BDNF signaling pathwayWP382:MAPK Signaling Pathway | |||||
| BDNF signaling pathway | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| NGF signalling via TRKA from the plasma membraneWP382:MAPK Signaling Pathway | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02122913) Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818). | ||||
| REF 3 | ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39. | ||||
| REF 4 | Clinical pipeline report, company report or official report of Loxo Oncology. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.